Luz Cortes, MD
Hematology & Oncology · Fajardo, PRNPI 1205897352
Payments from drug & device makers
Across 221 payments — averaging $15.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$451
- E.r. Squibb & Sons, L.L.C.$282
- AstraZeneca$272
- Johnson & Johnson$250
- Bristol Myers Squibb$210
- Merck$202
- plus $2K from 31 others
What the payments were for
- Food & beverage$3,36799%
- Education$401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 32 | $451 |
| E.r. Squibb & Sons, L.L.C. | 23 | $282 |
| AstraZeneca(2 entities) | 16 | $272 |
| Johnson & Johnson | 15 | $250 |
| Bristol Myers Squibb | 14 | $210 |
| Merck | 13 | $202 |
| Lilly USA, LLC | 13 | $190 |
| Seagen Inc. | 9 | $174 |
| Sanofi | 8 | $140 |
| Daiichi Sankyo Inc. | 8 | $139 |
| Taiho Oncology, Inc. | 9 | $125 |
| Genentech USA, Inc. | 6 | $115 |
| Pfizer | 7 | $106 |
| Amgen | 6 | $98 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $82 |
| Astellas Pharma US Inc | 5 | $79 |
| Puma Biotechnology, Inc. | 5 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $58 |
| AbbVie | 3 | $50 |
| Gilead | 2 | $33 |
| Foundation Medicine, Inc. | 2 | $26 |
| Karyopharm Therapeutics Inc. | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Morphosys, US Inc. | 1 | $22 |
| Tolmar Pharmaceuticals, Inc. | 1 | $21 |
| Eisai Inc. | 1 | $20 |
| Agios Pharmaceuticals, Inc. | 1 | $16 |
| Verastem, Inc. | 1 | $15 |
| Mirati Therapeutics, Inc. | 1 | $15 |
| Beigene USA, Inc. | 1 | $14 |
| GSK | 1 | $13 |
| Servier Pharmaceuticals LLC | 1 | $13 |
| Exelixis Inc. | 1 | $12 |
| Boehringer Ingelheim | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Epizyme, Inc. | 1 | $12 |
| Jazz Pharmaceuticals Inc. | 1 | $11 |
How this compares
$3,407 in reported general payments places this provider in the 25th percentile of 138 hematology & oncology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 32 | $536 |
| Tamoxifen Citrate | 21 | $515 |
| Hydroxyurea | 18 | $329 |
| Prednisone | 11 | $288 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Fajardo
- Mirelis AcostaSan Juan$6.3M
- Hector Velez CortesPonce$3.1M
- Luis FloresSan Juan$2.3M
- Noridza Rivera RodriguezSan Juan$2.1M
- Adelba Torres-LopezSan Juan$1.9M
- Maria Garcia PallasCaguas$1.8M
- Karina Arocho-GonzalezHato Rey$1.1M
- Jose Lozada CostasSan Juan$934K
- Fernando CabanillasSan Juan$916K
- Mayra Rivera FigueroaRio Piedras$745K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.